Delcath to file NDA in Q2; Nuron Biotech licenses flu vax to Mitsubishi Tanabe;

@FierceBiotech: Will 2012 see a big spike in biotech buyouts? Short answer: "You can never have enough pipeline." More | Follow @FierceBiotech

@JohnCFierce: Will biotech buyouts be the focus in Europe, following end of the mega-deal and a round of stock buybacks? Likely. Story | Follow @JohnCFierce

@RyanMFierce: Onyx Pharma's Matt Fust didn't say the company's for sale, but that it'd be an attractive takeover target. That sounds like selling to me. | Follow @RyanMFierce

@FierceMedDev: Device company Launch Medical investing $4.8 million in Bartlett expansion, via @MBJMemphis. Article | Follow @FierceMedDev

> After meeting with the FDA, Delcath Systems ($DCTH) plans to submit an application for approval of its chemosaturation therapy in the second quarter of 2012 as planned. Report

> TheStreet's Adam Feuerstein recapped some of the biotech stock action that took place during the J.P. Morgan conference, noting that companies with hepatitis C drugs in the pipeline did the best. Article

> Exton, PA-based Nuron Biotech has struck a licensing deal with Mitsubishi Tanabe Pharma to license its vaccine against Haemophilus influenza type b bacteria for the Japanese market. Release

Pharma News

 @FiercePharma: Our take on the Novartis job cuts: One thing's sure, no reps will strike in protest ($NVS). Article | Follow @FiercePharma

> Novartis to slash 2,000 US jobs, mostly in sales. Story

> Pfizer weighing baby-formula offers from Nestle, Danone. More

> It's final: Tasigna in, Sprycel out in NICE guidelines. Article

> Numbers hint that Pfizer's Lipitor strategy may work. News

> J&J whistleblower testifies in TX Risperdal case. Story

> Will last year's buybacks morph into more M&A for 2012? Item

And Finally... The Bill Gates-supported effort to rid India of polio hits a milestone. Report

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.